DGAP-News: CureVac : CureVac's COVID-19 Vaccine Candidate, CVnCoV, Demonstrated Efficient Protection of Non-Human Primates During SARS-CoV-2 Challenge Infection
CureVac : CureVac's COVID-19 Vaccine Candidate, CVnCoV, Demonstrated Efficient Protection of Non-Human Primates During SARS-CoV-2 Challenge Infection
DGAP-News: CureVac / Key word(s): Research Update/Study results CureVac : CureVac's COVID-19 Vaccine Candidate, CVnCoV, Demonstrated Efficient Protection of Non-Human Primates During SARS-CoV-2 Challenge Infection 11.01.2021 / 13:00 The issuer is solely responsible for the content of this announcement. CureVac's COVID-19 Vaccine Candidate, CVnCoV, Demonstrated Efficient Protection of Non-Human Primates During SARS-CoV-2 Challenge Infection - Data provided further evidence on immunogenicity and protective efficacy of CVnCoV - Induction of robust antibody and T cell responses at lower dose than tested in Phase 3 trial - Full lung protection of CVnCoV-vaccinated animals during SARS-CoV-2 challenge infection TÜBINGEN, Germany/ BOSTON, USA - January 11, 2021 - CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced the publication of preclinical data demonstrating the induction of robust antibody and T cell responses of its COVID-19 vaccine candidate, CVnCoV, in non-human primates. Furthermore, rhesus macaques were shown to be protected from challenge infection with SARS-CoV-2 following vaccination with 8µg of CVnCoV. The data provided important evidence on the immunogenicity and protective efficacy of CVnCoV at low doses, supporting the ongoing international clinical Phase 2b/3 efficacy study applying a 12µg dose. The full manuscript of the preclinical data is available on the pre-print server bioRxiv. "These data further strengthen the protective profile of our lead COVID-19 vaccine candidate, CVnCoV, and complement our recently published preclinical findings," said Dr. Mariola Fotin-Mleczek, Chief Technology Officer of CureVac. "Full protection of the lungs of vaccinated animals supports CVnCoV's potential in protecting humans from the devastating effects the virus has. We are very encouraged to see that CVnCoV exihibits its protective efficacy already at a low dose, which is even lower than the dose we advanced into late-stage human clinical testing." Within the study, CVnCoV was tested in rhesus macaques at 8µg per dose following a two-dose vaccination schedule at day 0 and day 28. Robust humoral and cellular immune responses include high levels of spike protein and RBD specific binding, virus neutralizing antibodies and T cells. Upon challenge infection, vaccinated animals showed a reduced viral load in the upper respiratory tract (nose and throat) and full protection of the lower respiratory tract (lungs), where the virus was not detectable. About CVnCoV CureVac Media Contact CureVac Investor Relations Contact
Forward-Looking Statements For further information, please reference the company's reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.
11.01.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
1159715 11.01.2021